Contracts › 75A50122C00082

75A50122C00082: This Acquisition Will Allow Barda to Invest Project Bioshield Funds for Late-Stage Clinical Development, Regulatory Approval for 2-PAM Autoinjectors (As a Drug/Device Combination Product) to Treat Organophosphate (OP) Poisoning, Including Nerve Agent

Awarded to Aktivax, Inc. by Office of Assistant Secretary for Preparedness and Response.

$45.3Mobligated

$220.2Mpotential value

31 December 2026current end date

See modifications, all subcontractors and funding in FedSift →

Contract	75A50122C00082
Awardee	Aktivax, Inc.
Awarding agency	Office of Assistant Secretary for Preparedness and Response
Awarding office	BARDA - ASPR / DAAPPO / BARDA DCMA
NAICS	541714 Research and Development in Biotechnology (Except Nanobiotechnology)
PSC	AN12 Health R&D Services; Health Care Services; Applied Research
Place of performance	CO
Offers received	2
Period of performance	30 September 2022 to 31 December 2026
Potential end	31 December 2039
Estimated recompete solicitation	Now / imminent (estimate, ~6 months before expiry)

Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 06 October 2026. The solicitation date is an estimate from the end date, not a posted date.